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Abstract
Background: The 21-kDa Vaccinia virus VH1-related (VHR) dual-specific protein phosphatase
(encoded by the DUSP3 gene) plays a critical role in cell cycle progression and is itself regulated
during the cell cycle. We have previously demonstrated using RNA interference that cells lacking
VHR arrest in the G1 and G2 phases of the cell cycle and show signs of beginning of cell senescence.
Methods: In this report, we evaluated successfully the expression levels of VHR protein in 62
hysterectomy or conization specimens showing the various (pre) neoplastic cervical epithelial
lesions and 35 additional cases of hysterectomy performed for non-cervical pathologies, from
patients under 50 years of age. We used a tissue microarray and IHC technique to evaluate the
expression of the VHR phosphatase. Immunofluorescence staining under confocal microscopy,
Western blotting and RT-PCR methods were used to investigate the localization and expression
levels of VHR.
Results: We report that VHR is upregulated in (pre) neoplastic lesions (squamous intraepithelial
lesions; SILs) of the uterine cervix mainly in high grade SIL (H-SIL) compared to normal exocervix.
In the invasive cancer, VHR is also highly expressed with nuclear localization in the majority of cells
compared to normal tissue where VHR is always in the cytoplasm. We also report that this
phosphatase is highly expressed in several cervix cancer cell lines such as HeLa, SiHa, CaSki, C33
and HT3 compared to primary keratinocytes. The immunofluorescence technique under confocal
microscopy shows that VHR has a cytoplasmic localization in primary keratinocytes, while it
localizes in both cytoplasm and nucleus of the cancer cell lines investigated. We report that the up-
regulation of this phosphatase is mainly due to its post-translational stabilization in the cancer cell
lines compared to primary keratinocytes rather than increases in the transcription of DUSP3 locus.
Conclusion: These results together suggest that VHR can be considered as a new marker for
cancer progression in cervix carcinoma and potential new target for anticancer therapy.
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Background
The human genome contains 61 genes for Vaccinia virus
H1-like, or 'dual-specific' protein phosphatases (DUSPs)
[1], most of which have poorly understood functions.
Many of these genes encode phosphatase that dephos-
phorylate the mitogen-activated protein kinases (e.g.
MKP1/DUSP1, PAC1/DUSP2, MKP3/DUSP6, etc) or regu-
late the cell cycle (e.g. CDC14A and CDC14B). A group of
19 of these phosphatases consists only of a catalytic
domain and have molecular weights of 18 – 26 kDa. One
of them is the 185-amino acid residues Vaccinia H1-
related (VHR), encoded by the DUSP3 gene [2], which
dephosphorylates and thereby inactivates the mitogen-
activated protein kinases Erk and Jnk in vivo. We have
recently reported that the level of VHR fluctuate during
the cell cycle: in early G1, VHR is barely detectable and
then it increases to reach a peak before mitosis. Further-
more, the elimination of VHR by RNA interference
resulted in cell cycle arrest in G1/S and G2/M [3,4]. This
effect of VHR knock-down was counteracted by down-
modulation of the levels of Erk and Jnk or by modest lev-
els of Mek and Jnk inhibitors. Based on these data we pro-
posed that VHR is important for cell cycle progression
because it tempers Erk and Jnk during the S and G2/M
phases of the cell cycle, where excessive activity of these
kinases can activate cell cycle check points. The permissive
role of VHR in cell cycle regulation prompted us to ask if
VHR levels are perturbed in cancer cells.
Uterine cervical cancer is an important health problem
[5]. Human papilloma virus (HPV) is strongly implicated
as a causative agent in the etiology of this type of cancer
[6], which is preceded by well-characterized squamous
intraepithelial lesions (SIL), only 10–15% of which will
progress to malignancy [7]. However, HPV infection alone
is not sufficient to induce cancer development. The role of
the immune response in controlling HPV infection and
subsequent development of SIL is indirectly established
by the increased frequency of HPV-associated lesions in
patients with depressed cell-mediated immunity. Indeed,
our laboratory has demonstrated that HPV infection is
associated with an abnormal cytokine production and
diminished APC density function in the normal transfor-
mation zone (TZ) where the majority of SIL occurs [8].
How HPV causes premalignant and malignant disease
appears to be a consequence of the signaling pathways
that are stimulated or repressed in cells to enable the virus
to replicate. Major targets of the viral proteins E6, E7 and
E5 include respectively p53, proteins encoded by the
retinoblastoma gene family and the MAPK activity [9].
Our laboratory has also showed that functional compo-
nents of the NF-kB signaling pathway are up-regulated
and sequestered in the cytoplasm of human papillomavi-
rus 16 (HPV16) transformed cell lines leading to a
reduced activity of NF-κB [10]. Mutations in p53 gene
have been also reported [11]. It is clear that more investi-
gations on signaling pathways are required to better
understand the tumorigenesis associated with HPV infec-
tions.
Methods
Case selections and microarray construction
Following approval from our institutional review board, a
tissue microarray (TMA) was constructed with 62 hyster-
ectomy or conization specimens showing the various
(pre) neoplastic cervical epithelial lesions and 35 addi-
tional cases of hysterectomy performed for non-cervical
pathologies, from patients under 50 years of age. The cases
were retrieved from the archived Tissue Bank at Liège Uni-
versity (Liège Biothèque: BTULg) and represented biop-
sies diagnosed between the years 1998 and 2006.
These cases were selected on the basis of availability of at
least one evaluable tissue representative hematoxylin and
eosin-stained slide and a paraffin block. For each case,
slides were reviewed to select a representative area. The
corresponding spot on the associated paraffin block was
then cored and placed on a tissue microarrayer (Beecher
Instruments, Sun Prairie, WI, USA). The TMA blocks were
constructed in doublets (2 spots for each diagnostic
entity) using 1 mm tissue cores (Alphelys, Plaisir, France).
The whole series supplied a total number of 194 spots
including duplicate of 11 L-SIL, 18 H-SIL, 12 SCC, 12 pri-
mary cervical adenocarcinoma (ADC) and 9 adenocarci-
noma in situ (AIS). From the cases without cervical
lesions, duplicate of 16 ectocervix and 19 endocervix tis-
ues were arrayed. The finalized arrays were then cut into 5
μm-thick sections and mounted on glass slides.
In addition to the formalin-paraffin embedded tissues
that were used for the TMA preparation, additional frozen
cervical biopsy specimens were retrieved from the Tumor
Bank of Liege University (BTULg). These biopsies
included 10 high-grade squamous intraepithelial lesions
(HSIL), 10 invasive squamous cell carcinoma (SCC) and
10 paired normal exocervical tissues from the same
patients. These biopsies were used to perform immun-
ofluorescence studies under confocal microscopy.
Immunohistochemistry and immunofluorescence
The tissue microarray slides were stained with antibodies
against VHR (Clone 237020 dilution 1:2500, R&D Sys-
tems, Minneapolis, MN) using a standard avidin-biotin
complex method. Tissue microarray slides were deparaffi-
nized with xylene, graded alcohol then rehydrated with
distilled water. Endogenous peroxidase activity was
blocked by placing the slides in 0.5% hydrogen peroxi-
dase/methanol for 10 minutes followed by a tap water
rinse. Background staining was reduced by incubatingBMC Cancer 2008, 8:147 http://www.biomedcentral.com/1471-2407/8/147
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slides in 0.3% bovine serum albumin/Tris-buffered saline.
Antigen retrieval entailed placing the slides in a pressure
cooker with an antigen unmasking solution (0.01 M cit-
rate buffer, pH 6.0) for 1 minute. Slides were subse-
quently incubated with the primary (4°C overnight), then
biotinylated secondary antibodies and streptavidin-biotin
peroxidase. 3'3' diaminobenzidine (DAB) was used as
chromogen and sections were counterstained with hema-
toxylin.
Immunofluorescence staining on the cervix biopsies was
performed with a monoclonal antibody directed against
VHR (Clone 24 dilution 1:2500, BD, San Diego, CA). The
primary antibodies were revealed with Alexa-488 conju-
gated secondary antibody together with TOTO-3 to stain
nuclei. The sections were mounted and viewed under a
confocal laser scanning microscopy TCS SP2 (Leica TCS
SP2, Van Hopplynus, Belgium).
For immunofluorescence and immunohistochemistry on
cells in culture, the cells were grown on poly-L-lysine
coated coverslips and fixed with 4% formaldehyde. The
fixed cells were permeabilized with 0.3% of Triton X-100/
PBS buffer then stained either with anti-VHR mAb (4 μg/
ml) (BD-transduction laboratories) or with p16 antibody
(NeoMarkers). After 3 washes, the primary Ab was
revealed with an Alexa-488 conjugated secondary Ab
together with TOTO-3 (Invitrogen) to stain nuclei and vis-
ualized under confocal microscopy. For immunohisto-
chemistry, the anti-VHR antibody was revealed using an
HRP secondary detection kit (Universal LSABTM 2 KIT/
HRP, Rabbit/Mouse, DakoCytomation). The stained cells
were mounted and visualized on light microscopy.
Scoring of immunohistochemical staining
The VHR immunostaining was scored semi-quantita-
tively. For staining intensity, 0 represented samples in
which VHR nuclear and/or cytoplasmic staining was
undetectable, whereas 1+, 2+, and 3+ denoted samples
with low, moderate, and strong staining, respectively. For
staining extent, in normal ectocervix and the various
grades of SIL, 1+ represented samples in which VHR
expression was detectable in the lower 1/3 of the epithe-
lium whereas 2+ denoted samples in which the lower 2/3
of the epithelium showed detectable VHR expression and
3+ represented those in which the immunoreactive cells
reached the upper epithelial 1/3. For the extent of staining
in SCC, normal endocervix, AIS and ADC, 1+ represented
samples in which VHR expression was detectable in up to
33% of the epithelium whereas 2+ denoted samples in
which 33–66% of the epithelium showed detectable VHR
expression and 3+ represented those in which more than
66% of the cells were stained. In order to provide a global
score for each case, the results obtained with the two
scales were multiplied, yielding a single scale with steps of
0 to 9. The microarrays were scored by 2 independent
observers and discrepancies were resolved during a con-
sensus session. To externally validate the staining patterns
observed in the TMA, full representative tissue sections of
10 SCC were randomly selected, stained with VHR and
scored using the same system as used with the microarray.
Cell Lines and primary keratinocytes
Five different cell lines derived from cervix cancer were
used in this study: HeLa, SiHa and CaSki (all positive for
HPV) and C33 and HT3 (HPV negative). Immortalized
human foreskin keratinocytes stably transfected with E6
and E7 (E6/E7) were previously described [12] and kindly
provided by F. Rosl (Heidelberg, Germany). The cells were
grown in DMEM medium (Dulbecco's modified Eagle's
medium; ICN; Flow Laboratories) complemented with
10% heated inactivated fetal calf serum (FCS), 30 units/
ml of penicillin, 30 μg/ml of streptomycin and 2 mM of L-
glutamine.
Primary keratinocytes (KN) were prepared from hysterec-
tomies. Fragments were plunged in a solution containing
gentamycin, fungizon and anti-mycoplasm. These frag-
ments were cut in smaller pieces, and then incubated in
trypsin-EDTA (Invitrogen) at 37°C under agitation for 1–
2 hours. The epithelium was scraped and cells were recov-
ered in FCS. After centrifugation, the cells were resus-
pended in K-SFM medium (Serum Free Media;
Invitrogen) complemented with EGF (0.1 ng/ml), pitui-
tary hormone (20–30 μg/ml) and gentamycin (5 μg/ml).
Cell lysates and Immunoblotting
Cells were lysed in 20 mM Tris-HCl at pH 7.5, 150 mM
NaCl, 5 mM EDTA containing 1% NP-40, 1 mM Na3VO4,
10 μg/ml aproptinin and leupeptin, 100 μg/ml soybean
trypsin inhibitor and 1 mM phenylmethylsulfhonyl fluo-
ride, incubated on ice for 30 min then centrifuged at
20,000 g for 20 min. The proteins were then resolved by
SDS-PAGE and transferred onto nitrocellulose mem-
brane. The membranes were immunoblotted with opti-
mal dilutions of monoclonal primary antibodies,
followed by an HRP conjugated anti-mouse secondary Ab.
The blots were developed by enhanced chemilumines-
cence (ECL kit, Amersham) according to the manufac-
turer's instructions.
RNA preparation and RT-PCR
Total RNA was extracted from primary keratinocytes and
the different cell lines using the High Pure RNA Isolation
Kit (Roche Diagnostics, Germany) according to the proce-
dures supplied by the manufacturer. Reverse transcription
was performed using the RT-PCR kit (Applied Biosystem,
Foster City, CA). The PCR reaction was performed using
VHR specific primers (5'-ATGTCGGGCTCGTTCGAGCTC-
3' and 5'-CTAGGGTTTCAACTTCCCCTC-3') and normal-BMC Cancer 2008, 8:147 http://www.biomedcentral.com/1471-2407/8/147
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ized with HPRT (5'-GTTGGATACAGGCCAGACTTT-
GTTG-3' and 5'-GATTCAACTTGCGCTCATCTTAGGC-3').
Results
VHR expression and localization in cervix biopsies
VHR expression at the protein level was studied using a
tissue microarray mounted in normal exocervix (n = 16),
low-grade SILs (n = 11), high-grade SILs (n = 18), invasive
SCCs (n = 12), normal endocervix (n = 19), adenocarci-
noma (n = 12) and adenocarcinoma in situ (n = 9). Semi-
quantitative evaluation of VHR staining is shown in figure
1. The VHR score was statistically higher in H-SILs and
SCCs (p < 0.0001 and p < 0.05 respectively) compared to
normal exocervical epithelium (Fig 1, upper panel). The
VHR score in ADC and AIS was also significantly higher in
ADC and AIS compared to normal endocervix (p < 0.05
and p < 0.0001 respectively) (Fig. 1 lower panel). The
VHR immunoreactivity was very low in the (para) basal
cell layers of the normal squamous epithelium (Fig. 2A,
panel a) whereas an intense staining was observed in H-
SIL and SCC (Fig. 2A, panels c and d). In contrast to nor-
mal epithelium, VHR was both nuclear and cytoplasmic
in H-SIL and SCC (Fig. 2A, panels c and d). High immu-
noreactivity of VHR was also observed in ADC and AIS but
no nuclear staining was detected in these two categories of
cervix cancer (Fig. 2A, panels e, f and g).
In order to confirm the localization differences of VHR in
cancer biopsies versus exocervix epithelium, we per-
formed immunofluorescence analysis under laser scan-
ning confocal microscopy. Figure 2B shows that VHR
phosphatase is barely detectable and localizes exclusively
in the cytosol of the keratinocytes of the normal exocervix.
In H-SIL, VHR is highly expressed and has both nuclear
and cytoplasmic localization in several cells of the epithe-
lium. However, in SCC, VHR is highly expressed com-
pared to the exocervix of the same patient, with mainly
nuclear and perinuclear localization (Fig 2B).
VHR in cervix cancer cell lines
By immunocytochemistry, the levels of VHR were much
higher in the cervix cancer cell lines compared to the pri-
mary keratinocytes (Fig. 3A). The presence or absence of
HPV in the cells did not affect VHR levels. While VHR was
excluded from the nucleus in primary keratinocytes, it was
partly nuclear in the cervix cancer cell lines. These obser-
vations were confirmed by immunofluorescence staining
and confocal microscopy (Fig. 3B). VHR was overex-
pressed in all the cell lines used compared to primary
keratinocytes and was localized in both cytoplasm and
nucleus in the cervix cancer cell lines, while it was barely
detectable and never nuclear in the primary keratinocytes
(Fig. 3B). The degree of VHR overexpression was esti-
mated by immunoblotting and densitometric VHR/Actin
ratio to be 1.5 to 2.7 higher in the cervix cancer cells com-
pared to normal cells (Fig. 4).
Semi-quantitative evaluation of the expression of VHR phosphatase in a neoplastic and pre-neoplastic cervical lesions Figure 1
Semi-quantitative evaluation of the expression of VHR phosphatase in a neoplastic and pre-neoplastic cervical 
lesions. A group of 62 hysterectomy or conization specimens showing the various (pre) neoplastic cervical epithelial lesions 
(L-SIL (n = 11), H-SIL (n = 18), SCC (n = 12), ADC (n = 12) and AIS (n = 9)) and 35 cases of hysterectomy performed for non-
cervical pathologies, from patients under 50 years of age was evaluated for the expression of VHR protein using IHC method 
on a tissue microarray. The score for VHR staining (staining intensity × staining extent) is presented on the y axis. Each point 
represents one patient and the average expression level is indicated by a bar. NEx, normal exocervix; NEnd, normal endocer-
vix; L-SIL, low-grade SIL; H-SIL, high-grade SIL; ADC, Adenocarcinoma; AIS, adenocarcinoma in situ. * p < 0.05 and ***p < 
0.0001.BMC Cancer 2008, 8:147 http://www.biomedcentral.com/1471-2407/8/147
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A/: Immunohistochemical demonstration of VHR in cervical tissues Figure 2
A/: Immunohistochemical demonstration of VHR in cervical tissues. a) In normal exocervical tissue, there is a spreaded weak 
positive staining. b) In L-SIL, the VHR staining is more pronounced but exclusively cytosolic. c) In H-SIL: strong staining of VHR 
in the cytosol as well as in few nuclei. d) In SCC : strong nuclear staining in an important number of cancerous cells. e) Cervical 
glandular cells of the normal endocervix show very weak and spreaded staining of VHR. In endocervical adenocarcinoma (f) 
and AIS (g) there is strong cytoplasmic staining of VHR. Brown color represents VHR specific staining and blue is the staining 
for nuclei. B/: Immunofluorescent staining, under laser scanning confocal miscroscopy, of cervical biopsies showing a low VHR 
immunoreactivity and absence of nuclear staining in exocervical epithelium and high VHR expression, nuclear and peri-nuclear 
localisation in H-SIL and SCC. Toto-3 (blue) was used to stain the nuclei and merged to VHR staining (green).BMC Cancer 2008, 8:147 http://www.biomedcentral.com/1471-2407/8/147
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VHR half life in cervix cancer cell lines and primary 
keratinocytes
To elucidate the molecular mechanism responsible for the
increased amounts of VHR protein in cervix cancer, we
first measured VHR mRNA in the cervix cancer cell lines
compared to primary keratinocytes by semi-quantitative
RT-PCR. These analyses showed that mRNA levels were
indistinguishable between the five cell lines and three dif-
ferent samples of primary keratinocytes derived from hys-
terectomies (Fig. 5A). These data suggest that the
VHR expression and localization in cervix cell lines and primary keratinocytes Figure 3
VHR expression and localization in cervix cell lines and primary keratinocytes. A/ Immunochemistry of VHR in primary kerati-
nocytes (a), in HPV positive, HeLa (b), SiHa (c) and CaSki (d) and HPV negative C33 (e) and HT3 (f) cell lines. Brown indicates 
the VHR specific staining and blue represents the hematoxylin staining of nuclei. B/ Immunofluorescent staining under confocal 
microscopy of the primary keratinocytes and cancer cell lines HeLa, CaSki, SiHa and C33. Green indicates the VHR specific 
staining and Red (TOTO-3) staining for the nuclei.
a b c
d e f
KN                           HeLa                  CaSki                       SiHa                         C33
A
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increased amount of VHR protein is not due to increased
transcription of DUSP3 locus or stabilization of the VHR
mRNA, but more likely caused by increased translation or
decreased degradation of VHR protein in the cancer cells.
We examined next the VHR protein turnover by CHX
chase and western blot analysis. Primary keratinocytes,
HeLa cells, C33 and E6E7 transformed cell lines were
incubated with CHX (50 μg/ml) for 1, 2, 4, 6 and 8 hours.
Cell lysates were prepared and VHR level versus actin were
analyzed by Western blot. After 2 hours of CHX treatment,
the level of the expressed VHR decreased by 50% in pri-
mary keratinocytes while it did not changed in HeLa, C33
or E6E7 cells up to 8 hours after CHX treatment (Fig 5B).
These results demonstrate that VHR half life in primary
keratinocytes is shorter than 2 hours and longer than 8
hours in the cancer cells tested.
Discussion
The development and progression of cervical carcinoma is
dependent on both genetic and epigenetic events, includ-
ing alterations in the cell cycle machinery at various
checkpoints. Indeed, cervical carcinoma is associated with
aberrant regulation of cyclins D1 and E [13], p16 [14],
p21 and p27 [15]. In the present work, we describe that
the new discovered cell cycle regulator, the dual-specificity
phosphatase VHR [3], is increased at the protein level in
five different cervix cancer cell lines positive (HeLa, CaSki
and SiHa) or negative (C33 and HT3) for HPV compared
to primary keratinocytes prepared from hysterectomies.
Thus, VHR expression is not related to the high risk
human papillomavirus.
Importantly, the elevated levels of VHR are not an artefact
of cell culture. In primary cervix cancer biopsies, VHR is
highly expressed in several cells of the epithelium of all
Quantification of VHR protein level Figure 4
Quantification of VHR protein level. A. Representative Western Blot analysis of cell lysates from three different primary kerat-
inocytes (KN) samples and five different cervix cancer cell lines. B. Densitometric ratio VHR/Actin for the different cell types 
of the Western blot shown in panel A. These results are representative of 5 independent experiments.BMC Cancer 2008, 8:147 http://www.biomedcentral.com/1471-2407/8/147
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the H-SIL analyzed in this study as well as in the SCCs,
ADC and AIS. The number of intensely stained cells
increased markedly in SCC cases. The staining for VHR
and p16 in serial sections showed that all the VHR-posi-
tive cells were also positive for p16 (not shown), which is
considered as a marker of cervical (pre)cancer cells [12].
This is not surprising since VHR is barely detectable in G1
phase cells, but gradually increases during the progression
of the cells to G2/M phase [3]. Thus, VHR, like p16, is a
marker of cells in cycle (S, G2 and M phases). These results
together suggest that VHR can be considered as a new
marker for cancer progression in cervix carcinoma.
We also found that VHR is a cytosolic protein in primary
keratinocytes, but localizes both in the cytoplasm and
nucleus in cervix cancer cells. VHR does not contain recog-
nizable nuclear localization or nuclear export sequences,
but is small enough to passively diffuse into the nucleus.
Thus, its exclusion from the nucleus in primary keratinoc-
ytes likely is an active process. Preliminary results from
our laboratory show that VHR associates with cyclins
(unpublished observation), perhaps explaining its reten-
tion in the nuclear or cytosolic compartments in normal
versus malignant cells. Thus, it appears that VHR location
may be connected to cell cycle-dependent transport of cyc-
lins or dysregulation of cyclins in cancer [16].
What may be purpose of elevated VHR in cervix cancer?
Based on our previous findings[3,4], we believe that VHR
is important for cell cycle progression because it tempers
Erk and Jnk during the S and G2/M phases of the cell
cycle, where excessive activity of these kinases can trigger
cell cycle arrest in G1/S or G2/M. Thus, by elevating the
levels of VHR, cancer cells would prevent Erk and Jnk from
A/: Electrophoretic pattern of semi-quantitative RT-PCR products of VHR mRNA performed with primers specific for VHR  (upper panel) and the housekeeping gene HPRT (lower panel) (A) Figure 5
A/: Electrophoretic pattern of semi-quantitative RT-PCR products of VHR mRNA performed with primers specific for VHR 
(upper panel) and the housekeeping gene HPRT (lower panel) (A). mRNA were prepared from primary keratinocytes from 3 
different hysterectomies and from 5 different cervix cancer cell lines as indicated on the panels. B/: CHX chase analysis by 
Western blot of primary keratinocytes (KN), HeLa, C33 and E6/E7 cell lines. Cells were treated with CHX (50 μg/ml) and 
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becoming too active in S through G2, while still allowing
them to drive G1 progression. In support of this view, it
was recently reported that both Erk and Jnk are less active
in cervix cancer cells than in premalignant lesions [18].
Finally, because VHR is regulated during cell cycle pro-
gression and because its suppression by RNAi[3] halts cel-
lular proliferation and induces cellular senescence, and,
more importantly, because of its overexpression in the
cervix cancer, we propose that VHR may be a good target
for anticancer therapy. An exciting possibility will be that
cervix cancer cells that have adapted to high levels of VHR
expression will be sensitive to VHR small inhibitors and
that untransformed cells are much less dependent on VHR
for proliferation and survival. We have indeed developed
novel multidentate small molecule inhibitors of VHR that
inhibit its enzymatic activity at nanomolar concentrations
in vitro, and are active at low micromolar concentrations
on several cell lines and primary cells. We have tested
these inhibitors on HeLa and primary keratinocytes and
demonstrate that they halt HeLa cells proliferation while
they have no effect on primary keratinocytes (Tautz L, sub-
mitted).
Conclusion
VHR is an important cell cycle regulator. Loss of this phos-
phatase causes senescence and prolonged hyperactivation
of Erk and Jnk pathways. Together with our new finding
reported in this manuscript, these results might ultimately
lead in the near future, to a pharmacological approach to
inducing senescence in tumor cells, which would be a rad-
ical approach to treating cancer.
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